Cancer-associated CD43 glycoforms as target of immunotherapy

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 752-762

  Tuccillo, Franca Maria ^a   Palmieri, Camillo ^c   Fiume, Giuseppe ^c   De Laurentiis, Annamaria ^c   Schiavone, Marco ^c   Falcone, Cristina ^c   Iaccino, Enrico ^c   Galandrini, Ricciarda ^d   Capuano, Cristina ^d   Santoni, Angela ^e   D'Armiento, Francesco Paolo ^b   Arra, Claudio ^a   Barbieri, Antonio ^a   Dal Piaz, Fabrizio ^f   Venzon, David ^g   Bonelli, Patrizia ^a   Buonaguro, Franco Maria ^a   Scala, Iris ^b   Mallardo, Massimo ^b   Quinto, Ileana ^c   Scala, Giuseppe ^c   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE; IMMUNOGLOBULIN G1; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; LEUKOSIALIN; MONOCLONAL ANTIBODY; UN1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN STRUCTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL CYCLE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VIVO STUDY; LEUKEMIA CELL LINE; LYMPHOBLASTOID CELL; LYMPHOBLASTOID CELL LINE; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE DISPLAY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; T LYMPHOCYTE; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD43; CANCER VACCINES; EPITOPES; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84896267878     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0651     Document Type: Article

References (50)

1. Kadaja-Saarepuu L, Looke M, Balikova A, Maimets T. Tumor suppressor p53 down-regulates expression of human leukocyte marker CD43 in non-hematopoietic tumor cells. Int J Oncol 2012;40:567-76.
2. Ostberg JR, Barth RK, Frelinger JG. TheRomangod Janus: a paradigm for the function of CD43. Immunol Today 1998;19:546-50. (Pubitemid 28557116)
3. Tassone P, Bond H, Bonelli P, Tuccillo F, Valerio G, Petrella A, et al. UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. Tissue Antigens 1994;44:73-82. (Pubitemid 24262459)
4. de Laurentiis A, Gaspari M, Palmieri C, Falcone C, Iaccino E, Fiume G, et al. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. Mol Cell Proteomics 2011;10:M111 007898.
5. Cecco L, Bond HM, Bonelli P, Tuccillo F, Cerra M, Tassone P, et al. Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues. Tissue Antigens 1998;51:528-35. (Pubitemid 28269222)
6. Tassone P, Tuccillo F, Bonelli P, D'Armiento FP, Bond HM, Palmieri C, et al. Fetal ontogeny and tumor expression of the early thymic antigen UN1. Int J Oncol 2002;20:707-11.
7. Tassone P, Bonelli P, Tuccillo F, Bond HM, D'Armiento FP, Galea E, et al. Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. Anticancer Res 2002;22:2333-40. (Pubitemid 34857062)
8. Bhutani D, Vaishampayan UN. Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opin Biol Ther 2013;13:269-82.
9. Hong CW, Zeng Q. Awaiting a new era of cancer immunotherapy. Cancer Res 2012;72:3715-9.
10. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325-38.
11. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6:404-14. (Pubitemid 46696551)
12. Bratkovic T. Progress in phage display: evolution of the technique and its application. Cell Mol Life Sci 2010;67:749-67.
13. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination-from allergy to cancer. Expert Opin Biol Ther 2009;9: 493-506.
14. Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine 2007;25:3032-7. (Pubitemid 46482734)
15. Arnaiz B, Madrigal-Estebas L, Todryk S, James TC, Doherty DG, Bond U. A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens. J Immune Based Ther Vaccines 2006;4:2.
16. James TC, Bond U. Molecular mimics of the tumour antigen MUC1. PloS ONE 2012;7:e49728.
17. Kozbor D. Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens. Immunol Res 2010;46:23-31.
18. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Immunol 2005;42:1121-4.
19. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, et al. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004; 173:394-401. (Pubitemid 38797365)
20. Geiser M, Schultz D, Le Cardinal A, Voshol H, Garcia-Echeverria C. Identification of the human melanoma-associated chondroitin sulfate proteoglycan antigen epitope recognized by the antitumor monoclonal antibody 763.74 from a peptide phage library. Cancer Res 1999; 59:905-10. (Pubitemid 29086747)
21. Shanmugam A, Suriano R, Chaudhuri D, Rajoria S, George A, Mittelman A, et al. Identification of PSA peptide mimotopes using phage display peptide library. Peptides 2011;32:1097-102.
22. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005;97:1663-70. (Pubitemid 41672232)
23. Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother 2005;54:677-84. (Pubitemid 40884164)
24. Bramswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res 2007;13:6501-8. (Pubitemid 350075041)
25. Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 2003;107:976-83. (Pubitemid 37429840)
26. Hartmann C, Muller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010;29:4517-27.
27. Palmieri C, Trimboli F, Puca A, Fiume G, Scala G, Quinto I. Inhibition of HIV-1 replication in primary human monocytes by the IkappaBalphaS32/36A repressor of NF-kappaB. Retrovirology 2004;1:45.
28. Fiume G, Vecchio E, De Laurentiis A, Trimboli F, Palmieri C, Pisano A, et al. Human immunodeficiency virus-1 Tat activates NF-kappaB via physical interaction with IkappaB-alpha and p65. Nucleic Acids Res 2012;40:3548-62.
29. Fiume G, Rossi A, de Laurentiis A, Falcone C, Pisano A, Vecchio E, et al. Eukaryotic initiation factor 4H is under transcriptional control of p65/NF-kappaB. PloS ONE 2013;8:e66087.
30. Capuano C, Paolini R, Molfetta R, Frati L, Santoni A, Galandrini R. PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. Blood 2012;119:2252-62.
31. Spatuzza C, Schiavone M, Di Salle E, Janda E, Sardiello M, Fiume G, et al. Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk. Nucleic Acids Res 2008;36:4402-16.
32. Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 2013;190:2381 -90.
33. Schiavone M, Fiume G, Caivano A, de Laurentiis A, Falcone C, Masci FF, et al. Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. Int J Mol Sci 2012;13:5674-99.
34. Puca A, Fiume G, Palmieri C, Trimboli F, Olimpico F, Scala G, et al. IkappaB-alpha represses the transcriptional activity of the HIV-1 Tat transactivator by promoting its nuclear export. J Biol Chem 2007; 282:37146-57.
35. Bonelli P, Tuccillo FM, Calemma R, Pezzetti F, Borrelli A, Martinelli R, et al. Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. Pharmacogenomics J 2011;11:412-28.
36. Fiume G, Rossi A, Di Salle E, Spatuzza C, Mallardo M, Scala G, et al. Computational analysis and in vivo validation of a microRNA encoded by the IBTK gene, a regulator of B-lymphocytes differentiation and survival. Comput Biol Chem 2009;33:434-9.
37. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47: 187-376. (Pubitemid 20010960)
38. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, et al. In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-speci fic peptide binder. Blood 2010;116: 226-38.
39. Causa F, Della Moglie R, Iaccino E, Mimmi S, Marasco D, Scognamiglio PL, et al. Evolutionary screening and adsorption behavior of engineered M13 bacteriophage and derived dodecapeptide for selective decoration of gold interfaces. J Colloid Interface Sci 2013; 389:220 - 9.
40. Paduano F, Ortuso F, Campiglia P, Raso C, Iaccino E, Gaspari M, et al. Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity. ACS Chem Biol 2012;7:1666-76.
41. Vitagliano L, Fiume G, Scognamiglio PL, Doti N, Cannavo R, Puca A, et al. Structural and functional insights into IkappaB-alpha/HIV-1 Tat interaction. Biochimie 93:1592-600.
42. Janda E, Palmieri C, Pisano A, Pontoriero M, Iaccino E, Falcone C, et al. Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkgamma. Blood 2011;117:6520- 31.
43. van Houten NE, Zwick MB, Menendez A, Scott JK. Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine 2006;24:4188-200.
44. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med 2001;7:1225-31. (Pubitemid 33069380)
45. Santana MA, Pedraza-Alva G, Olivares-Zavaleta N, Madrid-Marina V, Horejsi V, Burakoff SJ, et al. CD43-mediated signals induce DNA binding activity of AP-1, NF-AT, and NFkappa B transcription factors in human T lymphocytes. J Biol Chem 2000;275:31460-8.
46. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
47. Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods 2004;32:321-7. (Pubitemid 38201286)
48. Giebel LB, Cass RT, Milligan DL, Young DC, Arze R, Johnson CR. Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities. Biochemistry 1995;34:15430-5.
49. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90.
50. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279: 377-80. (Pubitemid 28063372)